ResearcherShanghai Jiao Tong UniversityActive in the last 2 years
Qian Zhan
Matched on ORCID iD 0000-0002-5726-2285; OpenAlex author ID A5102026645. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 30
2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: none · 2026: 2 papers
Papers 6
- Longitudinal analysis of circulating tumor DNA and CA19-9 dynamics in predicting disease relapse and monitoring treatment response in stage I-III pancreatic du… Last author DOI 10.1016/j.ejca.2026.117042↗
- Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observational Study. Last author DOI 10.1097/mpa.0000000000002511↗
- Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes. Last author DOI 10.1016/j.canlet.2024.217134↗
- Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
- LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-022-01272-w↗
- Preoperative Score to Stratify Recurrence Risk After Curative Resection of Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Cohort Study Co-author DOI 10.21203/rs.3.rs-697919/v1↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Baiyong Shen · 6 shared papers, 2021–2026 · strength 1.16
- Paper Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observationa… DOI 10.1097/mpa.0000000000002511↗
- Paper Longitudinal analysis of circulating tumor DNA and CA19-9 dynamics in predicting disease relapse and monitoring treatme… DOI 10.1016/j.ejca.2026.117042↗
- Paper Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes. DOI 10.1016/j.canlet.2024.217134↗
- Chenlei Wen · 4 shared papers, 2022–2026 · strength 0.89
- Paper Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observationa… DOI 10.1097/mpa.0000000000002511↗
- Paper Longitudinal analysis of circulating tumor DNA and CA19-9 dynamics in predicting disease relapse and monitoring treatme… DOI 10.1016/j.ejca.2026.117042↗
- Paper Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes. DOI 10.1016/j.canlet.2024.217134↗
- Xiaxing Deng · 4 shared papers, 2021–2026 · strength 0.75
- Paper Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observationa… DOI 10.1097/mpa.0000000000002511↗
- Paper Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes. DOI 10.1016/j.canlet.2024.217134↗
- Paper Preoperative Score to Stratify Recurrence Risk After Curative Resection of Resectable Pancreatic Ductal Adenocarcinoma:… DOI 10.21203/rs.3.rs-697919/v1↗
- Lingxi Jiang · 3 shared papers, 2024–2026 · strength 0.60
- Paper Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observationa… DOI 10.1097/mpa.0000000000002511↗
- Paper Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes. DOI 10.1016/j.canlet.2024.217134↗
- Paper Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. DOI 10.1038/s41591-023-02790-x↗
- Siyi Zou · 2 shared papers, 2021–2026 · strength 0.44
- Paper Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observationa… DOI 10.1097/mpa.0000000000002511↗
- Paper Preoperative Score to Stratify Recurrence Risk After Curative Resection of Resectable Pancreatic Ductal Adenocarcinoma:… DOI 10.21203/rs.3.rs-697919/v1↗
- Siyi Zou · 2 shared papers, 2022–2024 · strength 0.32
- Paper Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes. DOI 10.1016/j.canlet.2024.217134↗
- Paper LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ducta… DOI 10.1186/s13045-022-01272-w↗
- Siyi Zou · 1 shared paper, 2026 · strength 0.28
- Hao Chen · 1 shared paper, 2024 · strength 0.18
- Yu Jiang · 1 shared paper, 2021 · strength 0.15
- Weishen Wang · 1 shared paper, 2021 · strength 0.15
- Haoda Chen · 1 shared paper, 2021 · strength 0.15
- Yizhi Cao · 1 shared paper, 2022 · strength 0.14
- Yihao Liu · 1 shared paper, 2022 · strength 0.14
- Jiancheng Wang · 1 shared paper, 2022 · strength 0.14
- Pengyi Liu · 1 shared paper, 2022 · strength 0.14
- Jiejie Qin · 1 shared paper, 2024 · strength 0.13
- Xiaomei Tang · 1 shared paper, 2024 · strength 0.13
- Kailian Zheng · 1 shared paper, 2024 · strength 0.13
- Rémy Nicolle · 1 shared paper, 2024 · strength 0.13
- Shulin Zhao · 1 shared paper, 2024 · strength 0.13
- Pierre Laurent‐Puig · 1 shared paper, 2024 · strength 0.13
- Magali Svrcek · 1 shared paper, 2024 · strength 0.13
- Miaoyan Wei · 1 shared paper, 2024 · strength 0.13
- Jerome F. Cros · 1 shared paper, 2024 · strength 0.13
- Bin Song · 1 shared paper, 2024 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.